The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...

Faricimab should be readministered with caution in patients who develop mild intraocular inflammation with a previous dose of ...

Three experts discuss the increased mortality risk for patients with diabetic retinopathy, available screening tools, and counseling patients during eye exams.

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...